Outcomes with durvalumab by tumour PD-L1 expression in unresectable, stage III non-small-cell lung cancer in the PACIFIC trial

Paz-Ares, L.; Spira, A.; Raben, D.; Planchard, D.; Cho, B.; Ozguroglu, MUSTAFA; Daniel, D.; Villegas, A.; Vicente, D.; Hui, R.; Murakami, S.; Spigel, D.; Senan, S.; Langer, C.; Perez, B.; Boothman, A-M; Broadhurst, H.; Wadsworth, C.; Dennis, P.; Antonia, S.; Faivre-Finn, C.

doi:10.1016/j.annonc.2020.03.287

Outcomes with durvalumab by tumour PD-L1 expression in unresectable, stage III non-small-cell lung cancer in the PACIFIC trial

Paz-Ares L., Spira A., Raben D., Planchard D., Cho B. C., Ozguroglu M., ...Daha Fazla

ANNALS OF ONCOLOGY, cilt.31, sa.6, ss.798-806, 2020 (SCI-Expanded, Scopus)

Yayın Türü: Makale / Tam Makale
Cilt numarası: 31 Sayı: 6
Basım Tarihi: 2020
Doi Numarası: 10.1016/j.annonc.2020.03.287
Dergi Adı: ANNALS OF ONCOLOGY
Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus, Academic Search Premier, PASCAL, CAB Abstracts, EMBASE, MEDLINE
Sayfa Sayıları: ss.798-806
Anahtar Kelimeler: durvalumab, immunotherapy, non-small-cell lung cancer, PACIFIC, PD-L1 expression, stage III, DEATH-LIGAND 1, INHIBITORS, NSCLC
İstanbul Üniversitesi-Cerrahpaşa Adresli: Hayır

Özet

Background: In the PACIFIC trial, durvalumab significantly improved progression-free and overall survival (PFS/OS) versus placebo, with manageable safety, in unresectable, stage III non-small-cell lung cancer (NSCLC) patients without progression after chemoradiotherapy (CRT). We report exploratory analyses of outcomes by tumour cell (TC) programmed death-ligand 1 (PD-L1) expression.